Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn's Disease

JOURNAL OF CROHNS & COLITIS(2022)

Cited 0|Views15
No score
Abstract
In this real-world cohort of patients with CD, UST levels in the highest quartile (≥ 6.3 µg/mL) at week 8 were associated with higher biochemical remission rates at week 24.
More
Translated text
Key words
Crohn’s disease,Inflammatory bowel disease,Pharmacokinetics,Ustekinumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined